Stemirna Therapeutics, a Chinese biotech start-up focusing on RNA technology-based drug development, has raised nearly RMB100 million (US$14.16 million) in a serious A round of financing.
Chinese Biotech Start-Up Stemirna Therapeutics Raises $14M Series A Round comes originally from China Money Network. All Rights Reserved.